Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Investor Presentation (January 2021)
18 slides from Xoma Royalty's investor presentation, Jan 5, 2021
Slide 1: Corporate Presentation January 2021: A Royalty Aggregation Company
corporate PRESENTATION January 2021 NASDAQ: XOMA A Royalty Aggregation Company Exhibit 99.1
Slide 2: Disclaimers
DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions
Slide 3: XOMA Snapshot
Portfolio of 65+ assets in >30 disclosed indications today and growing Novartis – iscalimab, NIS793, gevokizumab Merck – MK-4830 Bayer - osocimab Acquire drug royalties associated with mid- to early stage clinical candidates Differentiate by focusing on development-stage assets with blockbuster pote
Slide 4: XOMA's Portfolio: 65+ Partnered Programs
Preclinical PHASE 1 Phase 1/2 Phase 2 Phase 3 BLA filing 1 Further Development Expenses by XOMA: $0 46 Assets with Large-Cap Partners 19 4 16 11 15+ XOMA’S PORTFOLIO: 65+ PARTNERED PROGRAMS
Slide 5: Program Advancements Since 2017
Since 2017 Strategic Pivot, Portfolio has seen 25 Advancements from Phase to Phase PROGRAM ADVANCEMENTS SINCE 2017
Slide 6: Key XOMA Portfolio Assets
Key xoma portfolio assets Asset Partner Royalty Rate Stage Iscalimab (anti-CD40) Novartis Mid-single digit to low-teens Phase 2 NIS793 (anti-TGFβ) Novartis Mid-single digit to low-teens Phase 2 MK-4830 (anti-ILT-4) Merck Low single digit Phase 2 Osocimab (anti-Factor Xia) Bayer Low single digit Phas
Slide 7: Novartis Pipeline
nda November 24, 2020 Al eT Novartis Group nc CEO wo) Pipeline RAD Pharmaceuticals I) NOVARTIS | Reims
Slide 8: Advancing iscalimab in a range of indications through 2020-26
Advancing iscalimab in a range of indications through 2020-26
Slide 9: XOMA Royalty Rates
XOMA Royalty Rates IscalimabMid-single digit to low teens VPM087Mid-single digit to low teens NIS793Mid-single digit to low teens NIR178Low-single digits
Slide 10: We Expect a Significant Number of Clinical Events in 2021
We Expect a Significant number of clinical events in 2021 As disclosed by partners on Clinicaltrials.gov dates as of 12/30/20 and public announcements all subject to change Sponsor/Program Phase 1 Phase 2 Phase 3 Regulatory Sesen/Vicineum JNJ/cetrelimab Novartis/iscalimab Novartis/NIR178 AVEO/ficlat
Slide 11: Who We Are: Board of Directors and Leadership
Board of Directors Denny Van Ness Hidden Hill Advisors Natasha Hernday Seattle Genetics Barbara Kosacz Kronos Bio Joe Limber Secura Bio Jim Neal XOMA Matthew Perry BVF Partners Jack Wyszomierski VWR International (retired) Leadership Jim Neal, CEO Tom Burns, CFO Business Development Team Legal Team
Slide 12: XOMA is Positioned to Monetize Royalties on Mid- to Early Stage Clinical Assets
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL COMMERCIAL > $100M $25M – $100M < $25M Capital per transaction Ligand Royalty Pharma HCRP XOMA is Positioned to Monetize Royalties on MID- TO EARLY STAGE CLINICAL ASSETS
Slide 13: Opportunities Abound for Royalty Monetization
327 2,601 442 288 1,544 Biotech & Pharma License Transactions consist of: Milestone payments Royalty obligations Companies’ funding needs increase over time Bloomberg data PHASE 3 Licensing Deals: PHASE 2 Licensing Deals: PHASE 1 Licensing Deals: Preclinical/other Licensing Deals: Opportunities Abou
Slide 14: XOMA Acquisition Transactions 2018-2020
Biotech Company Partner / Licensee # of Assets Acquired Capital Deployed Therapeutic Area Agenus 7 $15M ($1M milestone earned since) Immuno-Oncology Aronora 5 $9M Thrombotics Palobiofarma 6 $10M Oncology, NASH, Asthma Bioasis 4 $1.2M Lysosomal Storage Disorders XOMA Acquisition TRANSACTIONS 2018 - 2
Slide 15: Key Attributes of XOMA Target Assets
KEY ATTRIBUTES OF XOMA TARGET ASSETS MID- TO EARLY STAGE CLINICAL ASSETS Therapeutic area agnostic LONG DURATION OF MARKET EXCLUSIVITY Patent expiration or regulatory exclusivity Rx STRONG DEVELOPER/MARKETER Assets partnered with high-quality pharma / biopharma companies HIGH REVENUE POTENTIAL High
Slide 16: Financial Highlights
financial Highlights Expenses ($M) YE Cash ($M)
Slide 17: Partner-driven financial events
Partner-driven financial events $25M from Novartis, blend of cash and debt reduction $4.4M in milestones & other payments from Merck, Takeda, Rezolute Doubled number of royalty licenses since 2017 Acquired milestone & royalty interests in >20 programs, future assets from 2 technology platforms Out-l
Slide 18: What makes XOMA so exciting
XOMA holds 65+ current assets; pharmaceutical partners fund 100% of research & development costs Novartis – iscalimab, NIS793, gevokizumab Merck – MK-4830 Bayer - osocimab XOMA sources royalty rights through deep industry network XOMA constructs an increasingly diverse and expanding portfolio to inc